about
Activation of classical protein kinase C reduces the expression of human cationic amino acid transporter 3 (hCAT-3) in the plasma membraneTime from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trialsEvaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma.Canonical Notch signalling is inactive in urothelial carcinoma.Multiple mechanisms mediate resistance to sorafenib in urothelial cancerConcomitant downregulation of the imprinted genes DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial carcinomaThe long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells.Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapyHERV-K and LINE-1 DNA Methylation and Reexpression in Urothelial Carcinoma.Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer.Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.Which patients benefit the most from neoadjuvant chemotherapy in advanced bladder cancer?Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate.Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma.Epigenetics of urothelial carcinoma.Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell LinesLack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors.Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines.Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment.Target genes of recurrent chromosomal amplification and deletion in urothelial carcinoma.Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.MTDH/AEG-1 contributes to central features of the neoplastic phenotype in bladder cancer.HDACs and HDAC inhibitors in urothelial carcinoma - perspectives for an antineoplastic treatment.Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.Quality of life in patients with cisplatin-resistant urothelial cancer: Typical ailments and effect of paclitaxel-based salvage therapy.Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin.Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09).Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinomaPerioperative complications and oncological safety of robot-assisted (RARC) vs. open radical cystectomy (ORC).Rs11892031[A] on chromosome 2q37 in an intronic region of the UGT1A locus is associated with urinary bladder cancer risk.Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma.Rs710521[A] on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk.
P50
Q24541312-E2D6EDEE-5D30-41AB-B8EE-39E2A44A0115Q28280571-BDB99E9B-2BAC-4275-92C3-BC5EC0141EA0Q30489412-6A4BE0B9-7571-4E85-998E-DBFE4EF48DACQ33590414-B3D4719F-8725-4709-BFFA-E397418B2140Q34565523-1E670FD2-A859-43D3-936D-C94981C2CB68Q34685436-06DA03E6-6929-4DE1-BF3C-4DA37F79788CQ35142587-E999EA2E-41AB-4351-8435-0F25CDEC5115Q35683471-28986D8D-AF84-4DE9-8726-1CE4935ECB9EQ35771672-40E483ED-9E3E-42A4-8AE1-E9F773FCFAF3Q37199283-0CA3E7A5-63B7-4AF1-A2CE-EE71796BD01CQ37530329-7607E05B-CE14-4EE5-B5EC-F4DA29B8763EQ37555069-349B36D5-F27E-4ED0-844E-DAAD44307F9DQ37609437-17396D7C-8805-431D-960F-8CDBE3C136EAQ37898995-650B0A75-B7A2-490E-930B-485357F7B9AAQ38168391-09F273C4-3C8C-4E01-BA6A-FA8F2FC0D277Q38230837-55EDFA57-0413-42F5-8D4D-341FE860D9B9Q38271078-61E15C90-A6FA-4579-B55E-E48DF4762F05Q38647100-3430212B-1A95-477F-84FD-1F46FB91D46BQ38650264-BA593F27-F701-4F74-80A1-41DE32C649B1Q38654974-8B193A33-F3F7-480C-A8F1-A7ED48C33A64Q38723756-8F89EB7D-2A72-45E8-AF5C-C1DAEC07E276Q38816754-71C310D5-BACB-4D16-9432-2232310B25A2Q38976604-118798E9-8B35-4522-B6B3-0D59222D2ECAQ38980746-D92AE50E-0380-4471-966D-E582BF4102CEQ39016475-2A1B57B2-9EC7-4549-87EE-95E01C91794DQ39027362-9EB71D91-E0D8-4B67-966F-515DCAE23112Q39082161-3365D877-C981-4FCA-AC43-DE09F280C65BQ39303051-9010A520-F6D6-476F-AE4D-8A3F77E288F9Q39540757-D38D06BC-86AB-4B65-B97B-05E2ED9CEF78Q39709661-45E1266E-DD14-4796-9BAB-24E898CF2938Q39947030-27E10022-D930-4A77-B194-7B9ADE453453Q40294732-C0BB604A-CDC7-4B26-B002-BECA67ACE648Q41234114-DBA45CBA-D136-4D3C-B407-7A3235A097D8Q41492522-45BA47EC-D593-44B5-8813-07943A661418Q41744771-D5C82C4A-E6EF-415E-8F47-33998502548BQ41768357-073A5E8B-697F-4044-82B8-3F122AA05CB4Q42671865-16D44925-061C-43D2-9AFB-E147A3A19E29Q43435543-D68BE020-EFAD-4BFA-B3F7-E51DA99AEFB9Q43544386-079F5291-EB63-4086-BA46-2A71C3492412Q43562123-628889FD-2C0E-4E52-9FA6-7FC245BE8088
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
taighdeoir
@ga
wetenschapper
@nl
հետազոտող
@hy
name
Günter Niegisch
@ast
Günter Niegisch
@en
Günter Niegisch
@es
Günter Niegisch
@nl
Günter Niegisch
@sl
type
label
Günter Niegisch
@ast
Günter Niegisch
@en
Günter Niegisch
@es
Günter Niegisch
@nl
Günter Niegisch
@sl
prefLabel
Günter Niegisch
@ast
Günter Niegisch
@en
Günter Niegisch
@es
Günter Niegisch
@nl
Günter Niegisch
@sl
P214
P227
P244
P106
P1153
36553072300
P19
P21
P213
0000 0000 2292 2365
P214
P227
P244
n2018180420
P31
P496
0000-0001-6929-8691
P569
1979-01-01T00:00:00Z
P735
P7859
lccn-n2018180420